hPSCreg®
This website uses cookies to keep track of login sessions and for internal Matomo Statistics. See our Privacy Policy for details. This website uses cookies, learn more


ICGi019-B-1

Registration Summary:

HCM1f33-wt119

ICGi019-B-1

General

Cell Line
hPSCreg name ICGi019-B-1
Cite as:
ICGi019-B-1
Alternative name(s)
HCM1f33-wt119
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines No similar lines found.
Last update 9th November 2024
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider
Generator Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG)
Owner Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG)
Distributors
Derivation country Russia

External Databases
BioSamples SAMEA116823156

General Information
Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
Subclone of

Donor Information

General Donor Information
Sex male

Phenotype and Disease related information (Donor)
Diseases A disease was diagnosed.
Hypertrophic Cardiomyopathy
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • Hypertrophic Cardiomyopathy

Other Genotyping (Donor)
Is there genome-wide genotyping or functional data available?
No

Donor Relations
Other cell lines of this donor

External Databases (Donor)
BioSamples SAMEA6878100

Ethics

Also have a look at the ethics information for the parental line ICGi019-B .
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? Sinthego sgRNA were used for CRISPR/Cas9 gene editing
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General
The source cell information can be found in the parental cell line ICGi019-B.

Reprogramming method
Vector type Non-integrating
Vector Episomal
Genes
Is reprogramming vector detectable?
No
Methods used
PCR, Sequencing

Vector free reprogramming

Other
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Gelatin
Feeder cells Mouse embryonic fibroblasts
Passage method Enzymatically
TrypLE
O2 Concentration 20 %
CO2 Concentration 5 %
Medium Other medium:
Base medium: DMEM/F12
Main protein source: Knock-out serum replacement
Serum concentration: 15 %
Supplements
Glutamin-Alanin 2 mM
Penicillin-Streptomycin 1 %
NEEA 1 %
bFGF 10 ng/ml
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
Score:
Marker Present Absent
mCpG
OCT4
Morphology pictures
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
KRT18
Yes
Morphology
Smooth Muscle Cell
Ont Id: CL_0000192
In vitro spontaneous differentiation
Marker Expressed
ACTA2
Yes
Morphology
Neuron
Ont Id: CL_0000540
In vitro spontaneous differentiation
Marker Expressed
TUBB3
Yes
Morphology

Microbiology / Virus Screening

Genotyping

Karyotyping (Cell Line)
Has the cell line karyotype been analysed?
Yes
46,XY
HCM1f33-119w-karyotype.jpg
Passage number: 15
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Genetic Modification

Disease/phenotype related modifications
Hypertrophic cardiomyopathy
Synonyms
  • HCM
  • Cardiomyopathy, hypertrophic
  • Enlarged and thickened heart muscle
Genetic modifications
MYH7 (target)
Variant
14q11.2
NM_000257.4(MYH7):c.1977G>C correction
NP_000248.2:p.Met659Ile correction
Homozygous
rs1241603111
The mutation NM_000257.4(MYH7):c.1977G>C linked to the hereditary form of HCM in parental ICGi019-B was corrected by CRISPR/Cas9. The clinical significance of this mutation remains unknown to this day.